You Position: Home > Paper
Evaluating the role of Her-2 in endocrine therapy for breast cancer
( views:247, downloads:120 )
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1006-9801.2006.05.001
- Key Word:
- Her-2基因;乳腺癌;内分泌治疗
Abstract： 对于激素受体阳性、Her-2基因异常的乳腺癌患者,如何选择内分泌药物一直是临床医生面临的问题.综合目前大量资料显示,Her-2过度表达与临床疗效间存在显著的负性相关性,三苯氧胺和第三代芳香化酶抑制剂对该组患者均疗效较差.化疗或化疗联合赫赛汀应是该组患者的优先选择,内分泌治疗联合赫赛汀可作为治疗策略的研究方向.
- [1]Thurlimann B,Gelber RD,Senn HJ,etc.Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.[J].2005,16(10).
- [2]E, Tagliabue,R, Agresti,C, Ghirelli,etc.The early relapse of premenopausal patients after surgery for node-positive breast carcinoma.[J].2001,70(2).
- [3]Cardoso F,Piccart MJ,de Azambuja E,etc.Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.[J].2006,11(2).
- [4]Witton CJ,Reeves JR,Going JJ,etc.Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.[J].2003,200(3).
- [5]R J, Pietras,J, Arboleda,D M, Reese,etc.HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.[J].1995,10(12).
- [6]Beerli RR,Hynes NE.Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.[J].1996,271(11).
- [7]Borg, A.,Baldetorp, B.,Fernoe, M.,etc.ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer[J].1994,81(2).
- [8]Piccart Gebhart MJ,Procter M,Leyland Jones B,etc.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.[J].2005,353(16).
- [9]C Kent, Osborne,Jiang, Shou,Suleiman, Massarweh,etc.Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.[J].2005,11(2 Pt 2).
- [10]Francisco E. Gago,Mariel A. Fanelli,Daniel R. Ciocca.Co-expression of steroid hormone receptors (estrogen receptor α and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: Clinical outcome following tamoxifen-based adjuvant therapy[J].2006,98(1).
- [11]Grausporta D.,Beerli RR.,Daly JM.,etc.Erbb-2, the Preferred Heterodimerization Partner of All Erbb Receptors, is a Mediator of Lateral Signaling[J].1997,16(7).
- [12]Romond EH,Perez EA,Bryant J,etc.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.[J].2005,353(16).
- [13]Campiglio M,Pupa SM,Menard S,etc.Biologic and therapeutic role of HER2 in cancer.[J].2003,22(42).